research Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study
Baricitinib is effective and safe for treating severe alopecia areata.
Search
for
Sort by
Research
30 / 1000+ results research The Spectrum of Health Domains Important to Lupus Patients: Early Development of a Disease Activity Patient Reported Outcome
A new tool helps lupus patients and doctors better track symptoms and quality of life.
research Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan
Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.
research Measuring Patient Quality of Life Following Treatment for Alopecia
Alopecia treatments improve life quality but side effects can lessen this benefit; better use of quality of life measures is needed.
research Efficacy and Safety of Baricitinib in Adults with Alopecia Areata: Phase 3 Results from a Randomized Controlled Trial (BRAVE-AA1)
Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
research Lifestyle Changes in Women with Polycystic Ovary Syndrome
Lifestyle changes can improve body composition, excess male hormone levels, and insulin resistance in women with PCOS.
research Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
research Understanding Key Symptoms, Side Effects, and Impacts of HR+/HER2- Advanced Breast Cancer: Qualitative Study Findings
Patients with HR+/HER2- advanced breast cancer commonly experience fatigue, hair loss, and pain, which significantly affect daily activities.
research Among Scalp Non-Responder Patients with Eyebrow/Eyelash Regrowth in the First Year, Continued Treatment with Baricitinib Resulted in Meaningful Scalp Responses for Patients with Severe Alopecia Areata
Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
research Forging the Future: 2018 Alopecia Areata Research Summit Summary Report
The summit concluded that new treatments like Jak inhibitors show promise for Alopecia Areata and personalized approaches are needed.
research Alopecia Areata: A Review of Diagnosis, Pathogenesis, and the Therapeutic Landscape
New treatments for alopecia areata show promise, but standardized guidelines are needed.
research Autologous Platelet Concentrates in Aesthetic Medicine
Autologous platelet concentrates show promise in esthetic treatments but need more standardized research.
research Diagnosis And Management Of Alopecia Areata: A Saudi Expert Consensus Statement (2023)
Experts recommend personalized treatment plans for best outcomes in managing Alopecia Areata.
research Patient-Reported Burden of Severe Alopecia Areata: First Results from the Multinational Alopecia Areata Unmet Need Survey
Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.
research Topical Tofacitinib for the Treatment of Alopecia Areata Affecting Facial Hair
Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
research The Relationship Between Patient-Reported Severity of Hair Loss and Health-Related Quality of Life and Treatment Patterns Among Patients with Alopecia Areata
People with moderate hair loss from Alopecia Areata feel more impacted than those with no or almost complete hair loss, and are more likely to seek treatment.
research ‘You Lose Your Hair, What’s the Big Deal?’ I Was So Embarrassed, I Was So Self-Conscious, I Was So Depressed: A Qualitative Interview Study to Understand the Psychosocial Burden of Alopecia Areata
Alopecia Areata (AA) causes significant emotional distress, including feelings of embarrassment, depression, and anxiety, and impacts social interactions and daily activities.
research Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
research Eyebrow and Eyelash Alopecia: A Clinical Review
The review shows how to properly diagnose and treat the loss of eyebrow and eyelash hair.
research Alopecia Areata's Psychological Impact on Quality of Life, Mental Health, and Work Productivity: A Scoping Review
Alopecia areata severely impacts quality of life, mental health, and work productivity.
research Clinical Benefits of Baricitinib Therapy for Severe Alopecia Areata
Baricitinib treatment helps regrow eyebrow, eyelash, and scalp hair in severe alopecia areata, improving patients' emotional well-being and quality of life.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Development of the Alopecia Areata Patient Priority Outcomes Instrument: A Qualitative Study
Researchers created a new tool to measure the effects of alopecia areata from the patient's view, focusing on hair loss, daily life, and emotional health.
research Treatment of Hidradenitis Suppurativa Evaluation Study: The THESEUS Prospective Cohort Study
Laser treatment and deroofing are effective options for hidradenitis suppurativa.
research Anxiety in the Medically Ill: A Systematic Review of the Literature
Many patients with various medical conditions experience anxiety, which worsens their quality of life and raises healthcare costs.
research Clinician and Patient Evaluation of Improvement for Eyebrow and Eyelashes Hair Loss During Baricitinib Phase 3 Trials BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
research Choice of Recall Period for Patient-Reported Outcome Measures: Criteria for Consideration
Choosing the right recall period for patient feedback is important for accurate data and depends on the disease, symptom changes, and patient impact.
research PSS21 Gap Analysis for Patient-Reported Outcomes Measures for Alopecia
No current patient-reported outcome measure fully meets FDA requirements for alopecia treatments.
research Patient Experience in Systemic Lupus Erythematosus: Development of Novel Patient-Reported Symptom and Patient-Reported Impact Measures
New tools were created to help lupus patients report their symptoms and impacts more accurately.
research Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.